The observation that PAK1 depletion sensitized melanoma cell lines to cisplatin suggests that combination treatments of PAK1 inhibitors and DNA-damaging agents may improve chemoresponsiveness in certain human tumors (Ho et al., 2012). The gene discussed is PAK1; the disease is melanoma.